MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/mjt.0000000000001710

Медицинская библиотека · American journal of therapeutics · 2024

The Effect of ABCB1 and CES1 Polymorphisms on Plasma Levels of Dabigatran and Risk of Hemorrhagic Complications in Ischemic Stroke Patients.

Olšerová Anna, Janský Petr, Magerová Hana, Šrámková Tereza, Kešnerová Petra, Kmetonyová Silvia, Šulc Vlastimil, Halmová Hana, Šrámek Martin, Šarbochová Ivana, Paulasová-Schwabová Jaroslava, Benešová Kateřina, Macek Jan, Maťoška Václav, Tomek Aleš

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Dabigatran directly inhibits thrombin and is used in primary and secondary stroke prevention in individuals with nonvalvular atrial fibrillation. The prodrug dabigatran etexilate is absorbed by enteral P-glycoprotein (ABCB1) and then activated by hepatic and intestinal carboxylesterases (CES1) to produce active metabolites. Variations in dabigatran metabolism because of genetics may affect concentration levels and clinical outcomes.

STUDY QUESTION: We conducted a study to assess how polymorphisms in the CES1 (rs2244613) and ABCB1 (rs4148738) genes affect the through plasma level (c min ) of dabigatran and its correlation to clinical outcomes.

STUDY

DESIGN

Retrospective multicentric study of consecutive patients on dabigatran therapy. Examination of CES1 rs2244613 and ABCB1 rs4148738 polymorphisms, c min 12 hours after administration, clinical follow-up (ischemic stroke, major or clinically relevant hemorrhage, myocardial infarction, other thromboembolism, and death).

MEASURES AND OUTCOMES: A total of 432 patients received treatment for an average of 19.78 months (SD of 20.165). The sex distribution of the patients was 56.5% male, and the average age was 67.56 years (SD of 14.7). The ABCB1 variant genotype was present in 67.8% of patients, whereas 37.5% carried the CES1 polymorphism.

RESULTS

Compared with wild-type patients, patients with the CES1 variant had significantly lower dabigatran plasma levels (with a mean difference of 16.986; 95% confidence interval, 5.794-28.178 ng/mL, P = 0.003). We also found a significant risk of major bleeding in patients carrying the ABCB1 rs4148738 allele (hazard ratio = 1.99, confidence interval 95% 1.10 to 3.59, P = 0.024).

CONCLUSIONS

The CES1 variant genotype rs2244613 is closely linked with reduced c min of dabigatran. Carriers of the ABCB1 rs4148738 polymorphism exhibit a tendency toward higher plasma levels of dabigatran, which leads to a significantly increased risk of bleeding.

Для цитирования: Olšerová Anna, Janský Petr, Magerová Hana, Šrámková Tereza, Kešnerová Petra, Kmetonyová Silvia, Šulc Vlastimil, Halmová Hana, Šrámek Martin, Šarbochová Ivana, Paulasová-Schwabová Jaroslava, Benešová Kateřina, Macek Jan, Maťoška Václav, Tomek Aleš. The Effect of ABCB1 and CES1 Polymorphisms on Plasma Levels of Dabigatran and Risk of Hemorrhagic Complications in Ischemic Stroke Patients.. American journal of therapeutics. 2024. DOI: 10.1097/mjt.0000000000001710.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.